Formulation Development
Albireo Announces Exclusive Licensing Agreement With Jadeite Medicines
Albireo Pharma, Inc. recently entered into an exclusive licensing agreement with Jadeite Medicines, Inc. for the development and commercialization of Bylvay (odevixibat) in Japan for…
Processa Pharmaceuticals Cleared by FDA to Proceed with Phase 2a Trial for the Treatment of Gastroparesis
Processa Pharmaceuticals, Inc. recently announced it has been cleared by the US FDA to proceed with a Phase 2a clinical trial of PCS12852 in patients…
Agenus to Receive $20-Million Milestone Payment From Bristol Myers Squibb With Dosing of First Patient
Agenus Inc. recently announced it has triggered the first development milestone payment under its global licensing agreement with Bristol Myers Squibb for AGEN1777, an Fc-enhanced bispecific….
Metrics Contract Services Enters Partnership to Develop Oncology Drug
Metrics Contract Services, the US-based contract pharmaceutical development and manufacturing division of Mayne Pharma, recently announced the signing of a development and manufacturing agreement with….
MilliporeSigma Launches Excipient Technology Platform for Viscosity Reduction of Protein-Based Therapeutics
MilliporeSigma has recently launched a new Viscosity Reduction Excipient Platform to reduce the viscosity and help overcome manufacturing and formulation challenges associated with….
MannKind Announces First Patient Enrolled in INHALE-1 Study of Afrezza in Pediatric Population
MannKind Corporation recently announced the enrollment of the first pediatric patient in the INHALE-1 study. The multi-center study will evaluate the efficacy and safety of….
InMed Pharmaceuticals Announces Commencement of Phase 2 Clinical Trial Investigating Cannabinol (CBN), a Rare Cannabinoid, in the Treatment of Epidermolysis Bullosa
InMed Pharmaceuticals Inc. recently announced it has commenced its Phase 2 clinical trial of INM-755 (cannabinol) cream in the treatment of Epidermolysis Bullosa (“EB”). This marks the first time….
Avacta Group Announces Achievement of Preclinical Development Milestone in LG Chem Life Sciences Partnership
Avacta Group plc recently announced a preclinical development milestone has been achieved in the multi-target therapeutics development partnership with LG Chem Life Sciences, the life sciences division of the South Korean LG Group, triggering an….
Boehringer Ingelheim & OSE Immunotherapeutics Announce First Patient Dosed in Phase 1 Expansion Trial of SIRPα Antagonist Monoclonal Antibody BI 765063 in Combination With Anti-PD-1 Antibody Ezabenlimab, in Patients With Advanced Endometrium or Colorectal Tumors
Boehringer Ingelheim and OSE Immunotherapeutics SA recently announced that the first patient has been dosed in the expansion phase of the Phase 1 clinical trial…
Castle Creek Biosciences Expands its Innovative Gene Therapy Platform for Rare Genetic Connective Tissue Disorders Through Research Collaboration With Mayo Clinic
Castle Creek Biosciences, Inc. recently announced a research collaboration with Mayo Clinic to advance discovery and preclinical development of investigational gene therapy candidates for the…
Minerva Neurosciences Announces Study Results Demonstrating Bioequivalence of Phase 2b, Phase 3, & Planned Commercial Formulations of Roluperidone for Treatment of Negative Symptoms of Schizophrenia
Minerva Neurosciences, Inc. recently announced results from a pivotal bioequivalence study comparing the roluperidone formulations used in its late-stage Phase 2b and Phase 3 trials,…
DRUG DELIVERY - CAPRO(TM): A New Advance in Polymeric Drug Delivery
Bob Wieden and Chun Wang, PhD, discuss how significant challenges, coupled with the complexity and diversity of new pharmaceuticals, have fueled the development of a novel polymeric drug delivery platform that overcomes a great many bioavailability and delivery obstacles.
MANUFACTURING SOLUTIONS - Sterile Drug Product Manufacturing During a Global Pandemic
Ankit Agrawal, MSc, Ronald Aungst, Jr., PhD, Jonothan Hamer, MCIPS, and Barbara Solow, PhD, say with vaccines and treatments now available and yet more on the horizon, the first major manufacturing hurdles have been crossed; however, the finish line is still in the distance.
EXECUTIVE INTERVIEW - Emergent CDMO: Making the Impossible, Possible for Biopharma Innovators
Catherine Hanley, Vice President & Interim CDMO Business Unit Head at Emergent BioSolutions, discusses the company’s plans for current and future CDMO operations and client partnership opportunities.
ARTIFICIAL INTELLIGENCE - Attempting to Speed Up Vaccine Development to Combat the Next Pandemic
Lars Wegner, MD, in the wake of the huge impact Covid-19 has had around the world, presents a state-of-the-art mathematical modelling and algorithms approach to vaccine development to prevent the next pandemic.
EXECUTIVE INTERVIEW - Croda: Solutions for Your High Value Drug Products
Dr. Stephen Rumbelow, Life Sciences Research Fellow for Croda Inc., discusses polysorbates, a key excipient used for stabilizing drug molecules in injectable dosage forms.
DRUG DEVELOPMENT - Simplifying the Drug Development Journey
Fran DeGrazio explains how experienced and focused collaborators can provide guidance, support services, manpower, and intellect to make it easier to achieve all the goals needed in delivering a drug to a patient.
Croda Donates 1,000 Solar Panel Modules to Non-Profit Organizations
Croda International Plc, the name behind high-performance ingredients and technologies that are relied on by industries and consumers everywhere, has donated 1,000 SunPower solar panels…
WHITEPAPER - Must-Use Strategies to Successfully Transfer & Scale Your Pharmaceutical Product
Introduction Pharmaceutical companies are turning more frequently to external manufacturing partners for their development and production needs. A cornerstone of modern drug development strategy, contract…
Novigenix & Radbound University Medical Center Discover the First Blood-Based ImmunoTranscriptomic Biomarkers for Response to Anti-PD-1 Therapy
Novigenix SA recently announced release of the article Whole Blood Transcriptome Profiling Identifies DNA Replication and Cell Cycle Regulation as Early Marker of Response to Anti-PD-1 in Patients with Urothelial Cancer. Immune checkpoint inhibitors (ICIs) have become….
